Status:
COMPLETED
GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)
Lead Sponsor:
Shanghai 10th People's Hospital
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
18-45 years
Phase:
PHASE4
Brief Summary
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or...
Eligibility Criteria
Inclusion
- Female aged 18- 45;
- Meet 2003 Rotterdam criteria;
- overweight/obesity,BMI≥24kg/m2.
Exclusion
- any contraindication to dulaglutide (known or suspected hypersensitivity to dulaglutide or related products, previous acute pancreatitis or chronic pancreatitis, inflammatory bowel disease; personal history or family history of medullary thyroid carcinoma, or personal history of multiple endocrine neoplasia type 2)；
- treatment with any other drugs that may interfere with the trial, including traditional Chinese medicine, contraceptives, metformin, GLP-1RA or pioglitazone within the last 3 months；
- chronic kidney disease or severe liver dysfunction；
- malignant tumors；
- mental illness;
- pregnancy or lactation；
- inflammatory bowel disease;
- recent participation in other weight-loss research projects within the last 3 months.
Key Trial Info
Start Date :
May 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 10 2022
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04876027
Start Date
May 15 2021
End Date
May 10 2022
Last Update
August 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Tenth People' Hospital
Shanghai, Shanghai Municipality, China, 200072